VC, deals, startups
ZafGen Scores $14M Series B
Rebecca Zacks 11/17/08
Anti-obesity drug developer ZafGen closed a Series B financing worth $14 million, PE Hub reports, citing a regulatory filing. Third Rock Ventures and Atlas Venture supplied the funding for the Cambridge, MA-based startup, which Luke profiled in September.
